Dr Sang-Jin Pak Talks Biosimilar Markets: US vs Europe

This week on the podcast, we’re speaking with Sang-Jin Pak, MD, the executive vice president of Samsung Bioepis’ Commercial Division.
April 25, 2020
In April 2020, Samsung Bioepis launched Ontruzant, a biosimilar for trastuzumab, in the US market, in partnership with Merck. The company launched the same drug in Europe in 2018, and it was the first trastuzumab biosimilar in Europe. This earlier release of biosimilars in Europe is not an anomaly, as Europe has had a much easier time developing and launching biosimilars than the US, thanks to their decade-long head start in the industry. We sat down with Sang-Jin Pak, MD, the executive vice president of Samsung Bioepis’ Commercial Division, to discuss the differences between the US and Europe.



To learn more about Samsung Bioepis, visit samsungbioepis.com.

x-button

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars® is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2020 Intellisphere, LLC. All Rights Reserved.